Joana Goncalves Sells 7,000 Shares of Oruka Therapeutics (NASDAQ:ORKA) Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) insider Joana Goncalves sold 7,000 shares of the business’s stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $30.61, for a total value of $214,270.00. Following the transaction, the insider owned 1,518 shares of the company’s stock, valued at approximately $46,465.98. This represents a 82.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Oruka Therapeutics Stock Performance

NASDAQ:ORKA opened at $31.84 on Friday. The stock has a market cap of $1.54 billion, a price-to-earnings ratio of -16.76 and a beta of -0.41. The business has a fifty day moving average of $28.46 and a 200-day moving average of $19.57. Oruka Therapeutics, Inc. has a 1 year low of $5.49 and a 1 year high of $32.28.

Oruka Therapeutics (NASDAQ:ORKA) last released its earnings results on Wednesday, November 12th. The company reported ($0.55) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.01. On average, equities research analysts predict that Oruka Therapeutics, Inc. will post -3.41 EPS for the current year.

Hedge Funds Weigh In On Oruka Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in ORKA. Rhumbline Advisers increased its position in shares of Oruka Therapeutics by 6.1% during the third quarter. Rhumbline Advisers now owns 30,327 shares of the company’s stock valued at $583,000 after purchasing an additional 1,757 shares during the period. PNC Financial Services Group Inc. acquired a new stake in shares of Oruka Therapeutics during the 3rd quarter worth about $39,000. Russell Investments Group Ltd. acquired a new stake in shares of Oruka Therapeutics during the third quarter worth approximately $43,000. BNP Paribas Financial Markets raised its position in Oruka Therapeutics by 464.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock valued at $31,000 after purchasing an additional 2,306 shares during the last quarter. Finally, Legal & General Group Plc bought a new position in shares of Oruka Therapeutics in the second quarter valued at about $28,000. 56.44% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. Piper Sandler initiated coverage on shares of Oruka Therapeutics in a research note on Thursday. They set an “overweight” rating and a $75.00 target price for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oruka Therapeutics in a research note on Wednesday, October 8th. BTIG Research boosted their price target on shares of Oruka Therapeutics from $56.00 to $63.00 and gave the company a “buy” rating in a report on Thursday, November 13th. Jefferies Financial Group started coverage on Oruka Therapeutics in a research note on Thursday, November 13th. They issued a “buy” rating and a $45.00 price target for the company. Finally, Barclays initiated coverage on shares of Oruka Therapeutics in a research report on Monday, October 13th. They set an “overweight” rating and a $48.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $48.88.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.